Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 5286408, 6 pages
https://doi.org/10.1155/2017/5286408
Research Article

Increased Cathepsin D Correlates with Clinical Parameters in Newly Diagnosed Type 2 Diabetes

1Department of Internal Medicine, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
2Department of Medical Ultrasound, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China

Correspondence should be addressed to Dao Wen Wang; nc.ude.umjt.hjt@gnawwd

Received 19 July 2017; Accepted 24 September 2017; Published 10 December 2017

Academic Editor: Lance A. Liotta

Copyright © 2017 Lei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Cathepsin D has been recently implicated in insulin resistance and cardiovascular disease. This study was designed to investigate the relationship between cathepsin D and newly diagnosed type 2 diabetes. Methods. Circulating cathepsin D levels and metabolic variables were measured in 98 cases and 98 controls. Myocardial performance index “Tei index” that reflects both left ventricular systolic and diastolic function was measured with Doppler echocardiography in cases. Results. Newly diagnosed type 2 diabetes demonstrated significantly higher circulating cathepsin D concentrations than controls (median level: 227 ng/ml versus 174 ng/ml, ). In newly diagnosed type 2 diabetes, a significant correlation was found between cathepsin D levels and HOMA-IR (homeostatic model assessment of insulin resistance) (, ). In contrast, no significant correlation was found between cathepsin D levels and clinical parameters in the control group (all ). Interestingly, correlation analysis revealed a positive association between cathepsin D levels and Tei index in type 2 diabetes (, ). Conclusions. Increased levels of circulating cathepsin D are closely linked with the presence of type 2 diabetes, and cathepsin D might serve as a novel biomarker for cardiac dysfunction in newly diagnosed type 2 diabetes.